DukeNUS Medical School

Signature Seminar Series

Future Directions in CDK 4/6 and Endocrine Resistant HR+/HER2- Advanced Breast Cancer

ABOUT THE LECTURE

CDK4/6 inhibition added to a backbone of endocrine therapy has improved progression free survival over endocrine therapy alone in advanced, HR+/HER2- breast cancer and is now standard of care. The genomic landscape of CDK4/6 resistant disease thus far appears similar to endocrine resistant disease dominated by PIK3CA and ESR1 mutations; yet more comprehensive genomic studies are needed. Preclinical studies have shown that CDK4/6 inhibition can lead to a T cell inflammatory signature in vivo. Immunotherapeutic approaches in combination with and following CDK4/6 inhibition are underway. The effects of endocrine monotherapy and endocrine therapy with CDK 4/6 inhibition on host and tumor immunity are unknown. Furthermore, the effects of standard of care estrogen depletion on host immunity are unknown and possibly a barrier to dramatic therapeutic improvements in HR+ breast cancers. We have undertaken a clinical study to evaluate the impact of endocrine therapy with and without CDK 4/6 on host and tumor immunity in correlation with changing E1 and E2 levels.

Speaker: **Dr Sarah L. Sammons**
Assistant Professor of Medicine
Multidisciplinary Breast Program
Duke Cancer Institute

Host: **Dr Tira Tan**
Consultant, Medical Oncology
National Cancer Centre Singapore

Date: **Wednesday, 10 April 2019**

Time: **12.00 PM - 1.00 PM**
(Light refreshments will be served at 11.30 AM)

Venue: **Duke-NUS Medical School**
Meeting Room 7C, Level 7

Contact Person: **Ms Kathleen Chan, Duke-NUS Research Affairs Department**
Email: kathleen.chan@duke-nus.edu.sg

ABOUT THE SPEAKER

Sarah Sammons M.D., is a medical oncologist at Duke University Medical Center/ Duke Cancer Institute in Durham, North Carolina. Dr. Sammons has expertise in the clinical care of patients with breast cancer of all stages. Her scientific goals are to translate scientifically grounded treatment strategies into clinical trials with the goal of improving outcomes for patients with breast cancer. She has particular interest in areas of high need for new therapies including endocrine and CDK4/6 resistant and triple negative subtypes. Her current research is focused on understanding how estrogen deprivation and modulation in standard of care breast cancer treatment impacts host and tumor immunity. She has designed and implemented several clinical trials using genomic-derived and immunotherapeutic approaches.



** Please be informed that photography and videography may be taken by Duke-NUS authorized personnel during the event for publicity purposes.*